MetaCure is an international private company led by a team of passionate executive with a wealth of experience in the medical device field. MetaCure was incorporated in 2003 and ever since our first and foremost goal has been to serve the needs of type 2 diabetes patients and healthcare providers. We hope to use our research efforts to develop clinically effective one-time solutions that can treat type 2 diabetes safely and durably. Through investment in pioneering research and development, we wish to offer solutions that are cost effective and accessible to the millions of people who need them.
To date, more than 300 patients have been treated with our DIAMOND therapy in international multi-center trials, providing over eight years of successful clinical experience. Now, with a global presence across four continents, we are initiating commercial activities and expanding our clinical and R&D endeavors.
These core values help us pave the way towards our goals:
Learn more about our company at www.MetaCure.com
The number of people living with diabetes is growing exponentially and already exceeds half a billion. The iChallenge Diabetes program was created to educate and assist in the goal of lowering the incidence of type 2 diabetes. Through prevention education in developing countries we can make a positive impact on patient health. Our prevention program sponsors physicians, educators and our employees who are devoted to our cause and are willing to travel to take part in direct community education activities. If you are interested in finding out more, please contact us at global_csr@MetaCure.com.
We believe medical device education can benefit healthcare professionals and patients. Our grants aim to help physicians improve the care of their patients through support of educational activities and programs, particularly in our areas of scientific interest.
In granting support to an educational activity, we take into account the merit of the program and its compliance with our company policies and values. Awards are not influenced by business that could arise from the grant applicant. The applicant is not obligated to purchase, use or recommend the use of our products.
If you are interested in finding out more, please contact us at grants@MetaCure.com.
Experienced independent researchers who are interested in conducting trials may submit their proposal to IIT@MetaCure.com. Application for support for technical inputs (such as statistical analysis or medical writing) or funding (or products) support will be considered from scientific, compliance and business perspectives.
Lebovitz et al., ADA Congress, Chicago 2013 “Existence of a Triglyceride-dependent Glycemic Regulatory Pathway in Patients with Type 2 Diabetes”.
Wang et al. ADA Congress, Chicago 2013 “A Prospective Case-control Study To Compare The Efficacy Of Laparoscopic Placement Of Gastric Contraction Modulator (TANTALUS II®) Vs Supplementary Insulin Treatment In Obese T2DM Patients”.
Lebovitz et al., IDF Congress, Melbourne 2013 “Gastric Electrical Stimulation (GES) in T2DM Improves Long-term Glycemic Control Through a Triglyceride-dependent Mechanism”.
Professor of Medicine, the Division of Endocrinology and Metabolism/Diabetes at the State University of New York.
Professor of Medicine, Director Emeritus, Baker IDI Heart & Diabetes Institute Melbourne, Honorary President, International Diabetes Federation Melbourne, Australia.
Professor of Surgery, Director of Outpatient Clinic Rudolfinerhaus Privatklinik GmbH, Vienna, Austria.
Professor of Medicine, Chairman of the Department of Medicine, and Head of the Division of Endocrinology, Diabetes and Metabolism at the Asklepios Clinic St. Georg in Hamburg.
Professor of Medicine, Senior Physician at the Department for Internal Medicine, Diabetes, Gastroenterology, Endocrinology and Metabolic Diseases, Asklepios Klinik St. Georg, Hamburg, Germany.
Professor of Medicine, Director and Chair Department of Medicine, Dean of Development and International Affairs University of Dresden, Transcampus Dean and Chair and Honorary Consultant in Endocrinology and Diabetes, Diabetes and Nutritional Sciences Rayne Institute, Denmark Hill Campus King’s College London.
Professor of Surgery, University of Genoa Medical School, Founder, First President, and Honorary President of the Società Italia di Chirurgia dell’Obesità e delle malattie metaboliche (SICOB), Founder, First President, and Honorary President of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Professor of Surgery, Consultant Surgeon and Clinical Associate Professor (Honorary), Upper Gastrointestinal & Metabolic Surgery Division, Department of Surgery, The Chinese University of Hong Kong.
DIAMOND is a one-time intervention treatment for type 2 diabetes. It is based on stimulation of the stomach muscles by gastric contractility modulation (GCM) signals, generated by a small device that is implanted in the abdomen. As a result, the DIAMOND restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels. Additionally, GCM signals cause an earlier satiation effect resulting in sustained weight loss.
DIAMOND is intended for patients with type 2 diabetes who are obese and refractory to oral medication. Clinical trials have demonstrated durable glucose control and weight loss, with minimal side effects. Accordingly, DIAMOND could be a preferred treatment option for patients who are otherwise considered for injectable therapies.
Typical patient profile for DIAMOND therapy
The DIAMOND may used for up to 15 years before a replacement is needed1.
DIAMOND is implanted in a minimally invasive laparoscopic procedure under general anesthesia. Three leads are attached to the subserosal layer of the stomach and connected to the DIAMOND implantable pulse generator (IPG) which is placed in a subcutaneous pocket in the abdomen. The DIAMOND therapy poses a low rate of complications consistent with similar laparoscopic procedures. The most common adverse side effect is transient post-operative pain.
DIAMOND therapy, also known as gastric contractility modulation, was validated through several clinical trials across multiple centers in seven countries, including two multi-center, randomized, double-blind controlled studies and one long-term study. Selected publications are listed here.
If you have not referred patients for DIAMOND therapy before, we advise you to contact our referral support office for assistance and all the relevant information:
Tel +49 7112 204 560
Please send us your question by email and we’ll get back to you soon.
MetaCure Germany GmbH
Tel: +49 711 22045610
 Based on MetaCure’s estimate.